MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Benralizumab (Fasenra®)

Selected References

  • Agache I, et al. 2020. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 75(5):1023-1042.
  • Manetz S, et al. 2020. Successful pregnancy in setting of eosinophil depletion by benralizumab. J Allergy Clin Immunol Pract. S2213-2198(20)31335-0.
  • Middleton PG, et al. 2020. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 55:1901208.
  • National Center for Biotechnology Information. “PubChem Compound Summary for , Benralizumab” PubChem, Accessed 7 Oct 2024.
  • S. Food and Drug Administration. 2024. Fasenra® Prescribing Information. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf. Accessed on 9 Dec 2024.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.